SMCI
Super Micro Computer
-- 40.210 PLTR
Palantir
-- 70.960 NVDA
NVIDIA
-- 140.260 TSLA
Tesla
-- 351.420 INTC
Intel
-- 22.470 
NEWS
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment